SOURCE: Medistem Inc.

Medistem Inc.

September 28, 2011 03:38 ET

Medistem to Discuss Immunological Aspects of Endometrial Regenerative Cells at Providence Multiple Sclerosis Center

SAN DIEGO, CA--(Marketwire - Sep 28, 2011) - Medistem Inc. (PINKSHEETS: MEDS) announced today that its Chief Executive Officer, Thomas Ichim, will be giving an academic lecture at the Providence Multiple Sclerosis Center, in Portland, Oregon on Sept 28th, entitled "Stem Cell Transplants for Multiple Sclerosis: Time to Focus on the Mesenchymals?"

"We have previously published promising results in the area of adult stem cell therapy for treatment of multiple sclerosis," said Dr. Sergey Sablin, Vice President of Medistem. "The Endometrial Regenerative Cell product is conceptually appealing for treatment of this condition given that these stem cells have the triad of abilities to: a) modulate the immune system and thus potentially inhibit the autoimmune attack; b) differentiate into neuronal cells and thus possibly repair the damage that has been done; and c) produce growth/trophic factors, which would enhance the natural ability of the nervous tissue to heal itself. Some of these data have already been published in the peer-reviewed paper describing the first use of ERC in humans in the Journal of Translational Medicine (link to publication"

Multiple sclerosis is a condition affecting more than 400,000 patients in North America and 2.4 million worldwide. The Providence Multiple Sclerosis Center is a premier facility in Oregon and Southwest Washington for treating this patient population. Dr. Stanley Cohan, Director of the Center, has been involved in developing numerous drugs for multiple sclerosis including Interferon Beta-1a (Avonex) and Natalizumab (Tysabri), which are currently used by MS patients world-wide.

"Currently, Medistem is exploring more aggressive investigations in applying the ERC stem cell in the field of multiple sclerosis. We are very interested in learning from the experts at the Providence Multiple Sclerosis Center clinical aspects of developing protocols for this condition," said Thomas Ichim, CEO of Medistem.

Medistem's lead product, the Endometrial Regenerative Cell (ERC), is a type of mesenchymal stem cell that has recently been cleared by the FDA to begin a dose escalating Phase I clinical trial in patients with critical limb ischemia. The company is currently investigating other conditions in which these cells may be therapeutically beneficial.

About Medistem Inc.
Medistem Inc. is a biotechnology company developing technologies related to adult stem cell extraction, manipulation, and use for treating inflammatory and degenerative diseases. The company's lead product, the endometrial regenerative cell (ERC), is a "universal donor" stem cell being developed for critical limb ischemia. A publication describing the support for use of ERC for this condition may be found at ERC can be purchased for scientific use through Medistem's collaborator, General Biotechnology

Cautionary Statement
This press release does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This press release may contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information. Factors which may cause actual results to differ from our forward-looking statements are discussed in our Form 10-K for the year ended December 31, 2007 as filed with the Securities and Exchange Commission.

Contact Information

  • Contact:
    Thomas Ichim
    Chief Executive Officer
    Medistem Inc.
    9255 Towne Centre Drive
    Suite 450
    San Diego
    CA 92122
    858 349 3617
    858 642 0027
    twitter: @thomasichim


Keyword Cloud

View Website